Zealand Pharma A/S

CPSE:ZEAL Stock Report

Market Cap: DKK 31.1b

Zealand Pharma Past Earnings Performance

Past criteria checks 4/6

Zealand Pharma has been growing earnings at an average annual rate of 30%, while the Biotechs industry saw earnings growing at 18.5% annually. Revenues have been growing at an average rate of 74.1% per year. Zealand Pharma's return on equity is 42.8%, and it has net margins of 73.3%.

Key information

30.00%

Earnings growth rate

31.55%

EPS growth rate

Biotechs Industry Growth18.72%
Revenue growth rate74.06%
Return on equity42.80%
Net Margin73.34%
Next Earnings Update13 Nov 2025

Recent past performance updates

Recent updates

Zealand Pharma A/S' (CPH:ZEAL) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

Aug 29
Zealand Pharma A/S' (CPH:ZEAL) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

Clinical Catalysts And Roche Alliance Will Advance Obesity Amid Risks

Key Takeaways Major data from obesity drug trials and new industry alliances position the company for expanded future revenues, lowered commercialization risks, and greater global market access. Strong financial reserves enable self-funded innovation and product launches, with pipeline diversification aligning well with emerging trends in obesity treatment.

Analysts Are Updating Their Zealand Pharma A/S (CPH:ZEAL) Estimates After Its First-Quarter Results

Aug 17
Analysts Are Updating Their Zealand Pharma A/S (CPH:ZEAL) Estimates After Its First-Quarter Results

Is Zealand Pharma (CPH:ZEAL) Weighed On By Its Debt Load?

May 24
Is Zealand Pharma (CPH:ZEAL) Weighed On By Its Debt Load?

Most Shareholders Will Probably Find That The CEO Compensation For Zealand Pharma A/S (CPH:ZEAL) Is Reasonable

Mar 21
Most Shareholders Will Probably Find That The CEO Compensation For Zealand Pharma A/S (CPH:ZEAL) Is Reasonable

Zealand Pharma A/S (CPH:ZEAL) Analysts Are Way More Bearish Than They Used To Be

Feb 21
Zealand Pharma A/S (CPH:ZEAL) Analysts Are Way More Bearish Than They Used To Be

Analysts Just Made A Substantial Upgrade To Their Zealand Pharma A/S (CPH:ZEAL) Forecasts

Dec 22
Analysts Just Made A Substantial Upgrade To Their Zealand Pharma A/S (CPH:ZEAL) Forecasts

Analyst Forecasts For Zealand Pharma A/S (CPH:ZEAL) Are Surging Higher

Nov 09
Analyst Forecasts For Zealand Pharma A/S (CPH:ZEAL) Are Surging Higher

Rock star Growth Puts Zealand Pharma (CPH:ZEAL) In A Position To Use Debt

Oct 01
Rock star Growth Puts Zealand Pharma (CPH:ZEAL) In A Position To Use Debt

Revenue & Expenses Breakdown

How Zealand Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

CPSE:ZEAL Revenue, expenses and earnings (DKK Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 259,1106,6814611,272
31 Mar 2556-1,1864311,019
31 Dec 2463-1,079404920
30 Sep 2477-1,053314856
30 Jun 24368-712270790
31 Mar 24344-739244734
31 Dec 23343-704216685
30 Sep 23343-760205656
30 Jun 2392-986215605
31 Mar 23107-1,064241601
31 Dec 22104-966258614
30 Sep 2293-855273612
30 Jun 22104-845286606
31 Mar 22114-608231602
31 Dec 21109-755298582
30 Sep 21158-925416595
30 Jun 21161-1,012480595
31 Mar 21347-909575574
31 Dec 20192-669222596
30 Sep 20301-660300612
30 Jun 20255-545178596
31 Mar 2054-62479605
31 Dec 1941-57268561
30 Sep 1943-50868522
30 Jun 193352462486
31 Mar 192855150471
31 Dec 183858144438
30 Sep 183560149394
30 Jun 1874-36147375
31 Mar 1868-34652347
31 Dec 17136-27447324
30 Sep 17306-11258293
30 Jun 17307-10055274
31 Mar 17306-10261259
31 Dec 16231-15759262
30 Sep 16221-13851243
30 Jun 16189-15855237
31 Mar 16188-13948224
31 Dec 15188-11448212
30 Sep 1527-24648217
30 Jun 1578-17844212
31 Mar 1575-14739195
31 Dec 14154-6540180
30 Sep 14151-4731160

Quality Earnings: ZEAL has high quality earnings.

Growing Profit Margin: ZEAL became profitable in the past.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: ZEAL has become profitable over the past 5 years, growing earnings by 30% per year.

Accelerating Growth: ZEAL has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: ZEAL has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (71.7%).

Return on Equity

High ROE: ZEAL's Return on Equity (42.8%) is considered outstanding.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/08/29 17:12
End of Day Share Price 2025/08/29 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Zealand Pharma A/S is covered by 31 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yihan LiBarclays
Kerry HolfordBerenberg
Laura HindleyBerenberg